InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
RXEXEC Free
11/15/21 1:13 PM
profile icon
walhall Free
11/02/21 7:10 AM
profile icon
Twd101 Free
10/24/21 1:15 AM
profile icon
apdp Free
10/14/21 2:08 PM
profile icon
cvbtech Free
10/04/21 1:59 AM
profile icon
walhall Free
10/02/21 3:02 PM
profile icon
apdp Free
09/20/21 1:12 AM
profile icon
The Dude-Dude Free
09/16/21 8:47 PM
profile icon
childofike Free
09/16/21 6:50 PM
profile icon
walhall Free
09/16/21 4:11 PM
profile icon
apdp Free
09/16/21 1:56 PM
profile icon
walhall Free
09/16/21 5:39 AM
profile icon
cvbtech Free
09/13/21 12:40 PM
profile icon
Twd101 Free
09/12/21 10:32 PM
profile icon
cvbtech Free
09/11/21 12:56 PM
profile icon
Twd101 Free
09/11/21 1:57 AM
profile icon
Twd101 Free
09/10/21 7:57 PM
profile icon
cvbtech Free
09/10/21 9:23 AM
profile icon
Twd101 Free
09/10/21 8:55 AM
profile icon
Twd101 Free
09/09/21 10:56 PM
profile icon
cvbtech Free
09/08/21 10:55 PM
profile icon
cvbtech Free
09/06/21 1:46 AM
profile icon
walhall Free
09/05/21 4:17 PM
profile icon
apdp Free
09/05/21 1:39 PM
profile icon
cvbtech Free
09/04/21 8:28 PM
profile icon
Good Sport Free
08/08/21 5:44 PM
profile icon
apdp Free
08/03/21 4:19 PM
profile icon
cvbtech Free
08/02/21 4:32 PM
profile icon
walhall Free
07/31/21 7:27 AM
profile icon
apdp Free
07/26/21 12:33 AM
profile icon
apdp Free
07/15/21 1:18 PM
profile icon
cvbtech Free
07/15/21 12:14 AM
profile icon
cvbtech Free
07/15/21 12:12 AM
profile icon
cvbtech Free
07/15/21 12:11 AM

CardioVascular BioTherapeutics (fka CVBT) RSS Feed

Followers
39
Posters
156
Posts (Today)
0
Posts (Total)
3648
Created
04/08/05
Type
Free
Moderators
VENTURIS THERAPEUTICS (formerly Cardiovascular

Biotherapeutics or CVBT) is a dead, zombie company

that hasn't run a single clinical trial in nearly 15

years
.  Not even one patient (!) has been treated

since 2007.  Venturis Therapeutics is insolvent,

illiquid, and is controlled and run by an individual

who was accused by the U.S government of

embezzling $14 million from his previous company.

   Venturis' lawyer, Barry Cannaday of Dentons (one

of the largest law firms in the U.S.), withdrew from

representing Venturis in April 2021 because Dentons

is owed over $200,000 by Venturis, and Mr. Cannaday

attested that "there are currently no assets or

revenue streams" to pay Dentons.   Yet anonymous

advocates for Venturis (who I personally believe are

the company's desperate leadership) lie about public

facts
that are easily verifiable.  One of the most

absurd false claims is that there are (allegedly) two

ongoing pivotal clinical trials (see that particular

false claim below).  These "clinical trials" exist only

in cyberspace but not in the real world the rest of us

(including Dentons) live in.  That said, enjoy the

entertainment that lies below.  Hopefully it gives you

some good laughs - that's about all that's left from

this dead, zombie company.  Enjoy!




VENTURIS THERAPEUTICS (VT) OVERVIEW


VT  was almost bankrupted by the original


CEO, Daniel C. Montano, and was rescued by


Calvin Wallen, Grant Gordon and then CFO,


Mickael Flaa. 


VT had almost $40,000,000 in debt & was


effectively insolvent. The board of directors


who replaced the Dan Montano cronies


rehabilitated VT so that today the company has


almost zero debt and an comprehensive patent


portfolio. Under the disasterous management


of Dan Montano, the company had zero


patents. 




Our Approach in Science and Technology:




Venturis Therapeutics, Inc. is a clinical stage


biopharmaceutical company advancing novel



therapeutics to address diseases such as


diabetic wounds, severe ischemic heart disease


and

peripheral artery disease. Our pre-clinical


therapeutic programs include erectile


dysfunction,


infarct stroke, degenerative disk disease and


Parkinson’s Disease.


Venturis Therapeutics, Inc. is focused on


targeted delivery of next generation


molecules which will improve the quality of life


for those suffering from vascular dysfunction.






We employ human proteins from the Fibroblast


Growth Factor family. Our lead candidate


stimulates the growth of new blood vessels when


administered to ischemic organs and


tissues. These anatomical targets are shown in


our pipeline section of the website.


www.vt.care






VENTURIS THERAPEUTICS (VT) OVERVIEW


VT  was almost bankrupted by the original


CEO, Daniel C. Montano, and was rescued by


Calvin Wallen, Grant Gordon and then CFO,


Mickael Flaa. 


VT had almost $40,000,000 in debt & was


effectively insolvent. The board of directors


who replaced the Dan Montano cronies


rehabilitated VT so that today the company has


almost zero debt and an comprehensive patent


portfolio. Under the disasterous management


of Dan Montano, the company had zero


patents. 




Our Approach in Science and Technology:




Venturis Therapeutics, Inc. is a clinical stage


biopharmaceutical company advancing novel



therapeutics to address diseases such as


diabetic wounds, severe ischemic heart disease


and

peripheral artery disease. Our pre-clinical


therapeutic programs include erectile


dysfunction,


infarct stroke, degenerative disk disease and


Parkinson’s Disease.


Venturis Therapeutics, Inc. is focused on


targeted delivery of next generation


molecules which will improve the quality of life


for those suffering from vascular dysfunction.






We employ human proteins from the Fibroblast


Growth Factor family. Our lead candidate


stimulates the growth of new blood vessels when


administered to ischemic organs and


tissues. These anatomical targets are shown in


our pipeline section of the website.


www.vt.care
 






VENTURIS THERAPEUTICS OVERVIEW
 
Our Approach in Science and Technology:


 
Venturis Therapeutics, Inc. is a clinical stage biopharmaceutical company advancing novel



therapeutics to address diseases such as diabetic wounds, severe ischemic heart disease and



peripheral artery disease. Our pre-clinical therapeutic programs include erectile dysfunction,



infarct stroke, degenerative disk disease and Parkinson’s Disease.



Venturis Therapeutics, Inc. is focused on targeted delivery of next generation




molecules which will improve the quality of life for those suffering from vascular dysfunction.




 
 
We employ human proteins from the Fibroblast Growth Factor family. Our lead candidate



stimulates the growth of new blood vessels when administered to ischemic organs and


tissues. These anatomical targets are shown in our pipeline section.


vt.care


 
















Venturis Therapeutics (VT) is


a biotechnology company based


in Dallas, Texas. VT  has pivotal trials

 
 ongoing in Ischemic Heart Disease &

 
Diabetic Foot Ulcers.

 
VT has a comprehensive patent

 
portfolio protecting its  therapeutic

 
programs.






Venturis Therapeutics (VT) is


a biotechnology company based


in Dallas, Texas. VT  has pivotal trials

 
 ongoing in Ischemic Heart Disease &

 
Diabetic Foot Ulcers.

 
VT has a comprehensive patent

 
portfolio protecting its  therapeutic

 
programs.


 


Venturis Therapeutics (VT) is

a biotechnology company based

in Dallas, Texas. VT has ZERO (0) pivotal trials ongoing

in Ischemic Heart Disease & Diabetic Foot

Ulcers.

 




This is an image

from inside

Cardiovascular

Biotherapeutics/

Venturis

Therapeutics'

laboratory.

CVBT/VT has been

working to create

FGF-1 for the last

seven years. They have

yet to make a gram

of the molecule.

Cardiovascular

Biotherapeutics/

Venturis

Therapeutics

cannot be a viable

biotechnology company

without drug to sell.

It is likely that the

adminstration will never

start the production

of FGF-1 in the

near future,

making this company

dead in the water. 


Cardiovascular

Biotherapeutics/

Venturis Therapeutics

is run by a CEO

that has been accused

of embezzling money

by the United States

Federal Government.

He is supported by

Grant Gordon, a

drunkard, who has

failed to raise any

children or any money

for the company.

Venturis Therapeutics

is drawing closer to

bankruptcy as a result

of a $1 million dollar

judgement against

Venturis Therapeutics.

Cardiovascular

Biotherapeutics/

Venturis Therapeutics

has failed to conduct

any clinical trials in the

last fourteen (14) years.

Multiple independent

valuation studies have

valued Cardiovascular

Biotherapeutics/

Venturis Therapeutics

as worthless. The only

real value of

Cardiovascular

Biotherapeutics/

Venturis Therapeutics

is their management’s

personal computers.

Cardiovascular

Biotherapeutics/

Venturis Therapeutics

has failed to have any

activity in the last

seven years as a result

of the new

administration. There

have been no clinical

trial developments.

There has been no

company information

related to the the

public. There has been

no public activity

whatsoever. Our own

administration’s new

employees have

consistently fled the

company. Especially

after their own experts

admitted that

Cardiovascular

Biotherapeutics/

Venturis Therapeutics

was lying in the various

lawsuits they have

filed. Cardiovascular

Biotherapeutics/

Venturis Therapeutics

has chosen to spend

illegally acquired

money on suing the

former administration.

The ten(10) fraudulent

lawsuit have all

resulted in victories for

the former

administration and

Daniel C. Montano. The

most recent court

decision, confirmed by

the United States

Federal Court, has

awarded Dan Montano

a $1 million dollar

judgement against

Cardiovascular

Biotherapeutics/

Venturis Therapeutics.

The judgement gives

the former

administration the

ability to initiate a

debtor’s exam on

Cardiovascular

Biotherapeutics/

Venturis Therapeutics.

As a result of this

judgement most

shareholdres believe

Cardiovascular

Biotherapeutics/

Venturis Therapeutics

will have to file for

bankruptcy. Most

shareholders believe

that Cardiovascular

Biotherapeutics/

Venturis Therapeutics

is now a defunct

company. The

administration are all

accused and convicted

fraudsters. Calvin

Wallen III is accused of

lying and stealing and

fraud by the United

States Federal

Government. Other

administrators such as

Mike Flaa and Grant

Gordon have also been

consistently accused of

fraudulent activities.

Our entire

administration cannot

be trusted. They are

notorious for scheming

investors out of their

money. BUYER

BEWARE. THIS

COMPANY LIES AND

THIS COMPANY IS A

FRAUD.


DO NOT INVEST.

Board Info
Posts Today
0
Posts (Total)
3648
Posters
156
Moderators
New Post